Calls for papers
-
Vectura has announced that revenues from inhaled drugs rose 7.1% in the first half of 2018, with Flutiform revenues up 3.1% compared to the first half of 2017 and up 6.1% compared to the second… Read more . . .
-
According to Mundipharma, Napp Pharmaceuticals has launched the company’s Flutiform fluticasone propionate/formoterol fumarate k-haler breath-activated MDI in the UK. The launch is the first in Europe since Flutiform k-haler was approved for the treatment of… Read more . . .
-
Consort Medical subsidiaries Aesica and Bespak will manufacture Opiant Pharmaceuticals’ OPNT003 nalmefene nasal spray, the companies said. Earlier this year, Opiant announced that it would develop OPNT003 for the treatment of opioid overdose using the… Read more . . .
-
Glenmark Pharmaceuticals announced that it has received marketing approval from German authorities for its generic version of Seretide Accuhaler and said that the product will be marketed in Germany as “Salflutin.” The company acquired development… Read more . . .
-
Roivant Sciences has acquired global rights to Patara Pharma’s PA101 cromolyn sodium inhalation solution for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), the company said. The inhalation solution, which will… Read more . . .
-
United Therapeutics will pay MannKind Corporation $45 million up front and up to $50 million in milestone payments, plus potential double-digit royalties for a worldwide exclusive licensing and collaboration agreement for development and commercialization of… Read more . . .
-
Johnson & Johnson subsidiary Janssen Pharmaceutical has submitted an NDA for esketamine nasal spray for the treatment of treatment-resistant depression in adults, the company said. Janssen said that it plans to submit an MAA to… Read more . . .
-
Device developer Merxin has announced that a European generics company has acquired exclusive worldwide rights for development of a tiotropium/olodaterol product for the treatment of COPD using Merxin’s MRX004 softmist inhaler. Boehringer Ingelheim markets its… Read more . . .
-
Glenmark Pharmaceuticals said that it has acquired an exclusive license to market a generic tiotropium bromide dry powder inhaler in Western Europe. The DPI, a generic version of Boehringer Ingelheim’s Spiriva Handihaler for the treatment… Read more . . .
-
insys Therapeutics’ epinephrine nasal spray for the treatment of anaphylaxis has received Fast Track designation from the FDA, the company said. In June 2018, Insys said that a Phase 1 study of the nasal spray… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
October 28-October 30: Deutches Aerosol Therapie Symposium (DATS), Marburg, Germany